IVRO Signs MOU to Merge With a European Based Non-Animal Testing Focused Organization
InVitro International (OTCQB: IVRO) has announced signing a Memorandum of Understanding (MOU) to merge with an unnamed European-based organization specializing in non-animal testing. The target company has been operating in the European market for over 20 years. This strategic move aligns with IVRO's previously announced growth strategy focused on mergers and acquisitions.
The MOU has received unanimous approval from IVRO's Board of Directors. Financial details and timing of the merger will be disclosed upon finalization of the agreement. The company views this merger as an opportunity to expand its presence in the European market, where the non-animal testing movement originated and continues to show strong growth.
InVitro International (OTCQB: IVRO) ha annunciato di aver firmato un Memorandum of Understanding (MOU) per fondersi con un'organizzazione europea non nominata specializzata in test senza animali. La società target opera nel mercato europeo da oltre 20 anni. Questa mossa strategica è in linea con la strategia di crescita annunciata in precedenza da IVRO, che si concentra su fusioni e acquisizioni.
Il MOU ha ricevuto l'approvazione unanime dal Consiglio di Amministrazione di IVRO. I dettagli finanziari e i tempi della fusione saranno rivelati al termine dell'accordo. L'azienda considera questa fusione come un'opportunità per espandere la propria presenza nel mercato europeo, dove è nato il movimento per i test senza animali e continua a mostrare una forte crescita.
InVitro International (OTCQB: IVRO) ha anunciado la firma de un Memorando de Entendimiento (MOU) para fusionarse con una organización europea no nombrada especializada en pruebas sin animales. La empresa objetivo ha estado operando en el mercado europeo durante más de 20 años. Este movimiento estratégico se alinea con la estrategia de crecimiento previamente anunciada por IVRO, centrada en fusiones y adquisiciones.
El MOU ha recibido la aprobación unánime de la Junta Directiva de IVRO. Los detalles financieros y el calendario de la fusión se revelarán una vez finalizado el acuerdo. La empresa ve esta fusión como una oportunidad para expandir su presencia en el mercado europeo, donde nació el movimiento de pruebas sin animales y sigue mostrando un fuerte crecimiento.
인비트로 인터내셔널 (OTCQB: IVRO)가 동물 실험을 하지 않는 것을 전문으로 하는 이름 없는 유럽 기관과 합병하기 위한 양해각서(MOU)를 체결했다고 발표했습니다. 대상 회사는 20년 이상 유럽 시장에서 운영되고 있습니다. 이번 전략적 움직임은 인비트로가 이전에 발표한 인수합병 중심의 성장 전략과 일치합니다.
MOU는 인비트로의 이사회에서 만장일치로 승인되었습니다. 합병의 재정적 세부사항과 일정은 계약이 최종화된 후에 공개될 것입니다. 회사는 이 합병을 유럽 시장에서의 존재감을 확장할 수 있는 기회로 보고 있으며, 이곳은 동물 실험을 하지 않는 운동이 시작된 곳이며 여전히 강한 성장을 보여주고 있습니다.
InVitro International (OTCQB: IVRO) a annoncé la signature d'un protocole d'accord (MOU) pour fusionner avec une organisation européenne non nommée spécialisée dans les tests sans animaux. L'entreprise ciblée opère sur le marché européen depuis plus de 20 ans. Ce mouvement stratégique s'aligne avec la stratégie de croissance précédemment annoncée par IVRO, axée sur les fusions et acquisitions.
Le MOU a reçu l'approbation unanime du conseil d'administration d'IVRO. Les détails financiers et le calendrier de la fusion seront révélés lors de la finalisation de l'accord. L'entreprise considère cette fusion comme une opportunité d'élargir sa présence sur le marché européen, où le mouvement pour les tests sans animaux a vu le jour et continue de montrer une forte croissance.
InVitro International (OTCQB: IVRO) hat die Unterzeichnung eines Memorandum of Understanding (MOU) zur Fusion mit einer nicht benannten europäischen Organisation, die auf tierversuchsfreies Testen spezialisiert ist, bekannt gegeben. Das Zielunternehmen ist seit über 20 Jahren auf dem europäischen Markt tätig. Dieser strategische Schritt steht im Einklang mit IVROs zuvor angekündigter Wachstumsstrategie, die sich auf Fusionen und Übernahmen konzentriert.
Das MOU erhielt die einstimmige Zustimmung des Vorstands von IVRO. Finanzielle Einzelheiten und der zeitliche Rahmen der Fusion werden bei Abschluss der Vereinbarung bekannt gegeben. Das Unternehmen sieht diese Fusion als Gelegenheit, seine Präsenz im europäischen Markt auszubauen, wo die Bewegung für tierversuchsfreies Testen entstanden ist und weiterhin stark wächst.
- Strategic expansion into the established European non-animal testing market
- Alignment with previously announced M&A growth strategy
- Board unanimously approved the merger MOU
- Financial terms and timing of the merger not disclosed
- Target company remains unnamed, limiting investor ability to assess deal value
Placentia, California--(Newsfile Corp. - January 14, 2025) - InVitro International (OTCQB: IVRO) previously revealed its strategic intent to accelerate organic growth by pursuing mergers and acquisitions. Today we are excited to announce our initial action to implement this strategy. InVitro International's Board of Directors unanimously approved a Memorandum of Understanding (MOU) to merge with a European based non-animal testing focused organization which has served their market for more than two decades. Details regarding costs and timing of the agreed upon MOU will continue when the agreement is finalized.
CEO W. Richard Ulmer observed: "The global movement toward the humane goal of sparing animals from safety testing began in Europe and continues to grow nicely there. InVitro International believes it can participate to a greater extent as we move forward together."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236957
FAQ
What European company is IVRO planning to merge with?
What is the value of IVRO's European merger deal?
When will IVRO's European merger be completed?
How does this merger align with IVRO's growth strategy?
What is the strategic importance of Europe for IVRO's expansion?
